Status message

Active context: kki_bg_colors_yellow

Methylphenidate in the Treatment of Hyperactivity and Implusiveness in Children and Adolescents with Pervasive Developmental Disorders

Principal Investigator:

This application is a request for transfer of this protocol from paper IRB to e-irb submission review:

This trial has ended. No children will be enrolled or participate in a clinical trial. We request that this protocol remain open until data analyses have been completed.

This study evaluated the efficacy and safety of guanfacine for treating hyperactivity, impulsiveness, and distractibility in 25 (permission for 60 subjects was requested) children and adolescents (aged 4.5 - 14 years) with Pervasive Developmental Disorder. Five sites (KKI, OSU, IU, Yale, and UCLA) participated in the trial. 8 children were enrolled at the KKI site.

Please note: At KKI, the methylphenidate and guanfacine arms of protocol were submitted and approved as 2 separate protocol applications.


Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.